TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The FDA approved bepirovirsen, used with existing antiviral therapy, for certain adults with chronic hepatitis B and no cirrhosis. In two phase III trials, about 19% to 20% of eligible participants reached a functional cure by week 72, compared with none in the placebo group; the treatment carries serious warnings and requires blood-test monitoring.
The U.S. Food and Drug Administration approved bepirovirsen on Tuesday for some adults with chronic hepatitis B who do not have cirrhosis and are already taking antiviral medication. The approval follows two phase III trials in which about one in five eligible patients achieved a functional cure by week 72, compared with none receiving placebo alongside their background treatment.
The approved use is limited to adults who have taken nucleos(t)ide analog antiviral therapy for at least six months, have suppressed levels of hepatitis B virus in their blood, and have hepatitis B surface antigen (HBsAg) levels of 3,000 IU/mL or less. Bepirovirsen is given as a six-month course alongside the existing antiviral; patients may self-administer it after the first dose, according to the report.
In the B-Well 1 and B-Well 2 trials, 19% to 20% of participants with HBsAg levels at or below 3,000 IU/mL met the functional-cure outcome at week 72. Among those with levels at or below 1,000 IU/mL, the reported rate was 26%. The source report says no participants in the placebo group achieved that outcome. These results describe trial participants meeting the stated criteria, not all people with chronic hepatitis B.
The most commonly reported side effects were injection-site reactions, fatigue, fever and headache. The FDA-approved prescribing information carries a boxed warning about serious hepatic flares during treatment and low platelet counts, which may lead to life-threatening thrombocytopenia. The label also warns about worsening kidney function, serious inflammatory reactions such as vasculitis, and risks related to improper injection. Regular blood tests are required, and bepirovirsen is not recommended for people with hepatitis D coinfection.
A Chance to Stop Long-Term Therapy
Chronic hepatitis B can cause serious liver disease, including cirrhosis, and the source report says more than half of liver cancer cases globally can be attributed to hepatitis B. For eligible patients, the significance of the approval is the possibility that a defined course of an additional medicine could allow them to maintain control of the virus after chronic HBV treatment ends.
The result is not a cure for everyone, and the approval does not replace ongoing antiviral therapy for all patients. The trial rates show that most participants did not meet the functional-cure outcome by week 72. Patients also face safety risks that require monitoring. The treatment’s value will depend on how benefits and harms compare in clinical use and how reliably the trial outcomes translate to eligible patients outside the studies.
As an affiliate, we earn on qualifying purchases.
The Trial Evidence Behind Approval
The FDA based its decision on findings from the B-Well 1 and B-Well 2 phase III trials. The studies assessed bepirovirsen alongside background antiviral treatment, rather than as a stand-alone replacement during the course. The reported functional-cure rates are tied to the week-72 assessment and to patients’ HBsAg levels.
Investigator Norah Terrault of the Keck School of Medicine at the University of Southern California described the approval as “the start of a new era” in a statement from drugmaker GSK. FDA official Wendy Carter said the medicine offers some patients the possibility of maintaining viral control after all chronic HBV treatment has ended. Those statements express the potential of the treatment; the reported trial results set out the measurable outcome and its limits.
“This is the start of a new era in treating people living with chronic hepatitis B.”
— Norah Terrault, MD, trial investigator at the Keck School of Medicine of USC
self-administered hepatitis B treatment
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Limits and Safety Questions
The source report does not provide the full trial data, including the number of participants, detailed definitions of functional cure, or a breakdown of outcomes across all patient groups. It also does not establish how long viral control lasts after treatment ends, or whether additional courses or other interventions may be needed. The reported week-72 figures should not be read as a guarantee of lasting control for an individual patient.
The approval excludes people with cirrhosis and sets specific requirements for prior treatment, suppressed blood virus levels and HBsAg levels. How the medicine performs in routine care, including the frequency and severity of serious adverse events, remains to be seen. The label’s warnings mean that monitoring and decisions about use require clinician oversight.
liver health monitoring blood test kits
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Monitoring After the FDA Decision
Clinicians and patients will need to follow the approved prescribing information, including eligibility criteria, blood-test monitoring and precautions for the boxed warnings. The next practical questions include how often eligible patients achieve sustained control after completing the six-month course and how treatment risks are managed in routine practice.
The source report does not give a timetable for additional studies or post-approval data. Further evidence will be needed to clarify longer-term outcomes and how well the trial findings apply across the population of adults who meet the FDA’s criteria.
As an affiliate, we earn on qualifying purchases.
Key Questions
Who is eligible for bepirovirsen under the FDA approval?
The approval covers adults with chronic hepatitis B who do not have cirrhosis, have taken nucleos(t)ide analog antiviral therapy for at least six months, have suppressed HBV blood levels and have HBsAg levels of 3,000 IU/mL or less. The treatment is used alongside the existing antiviral.
Does the approval mean bepirovirsen cures everyone with hepatitis B?
No. In the reported trials, about 19% to 20% of eligible participants with HBsAg levels at or below 3,000 IU/mL achieved a functional cure at week 72. The reported rate was 26% among those at or below 1,000 IU/mL.
How long is the bepirovirsen course?
The report describes a six-month course. Bepirovirsen is used with background antiviral therapy, and patients may self-administer it after the first dose.
What safety risks did the FDA highlight?
The prescribing information includes a boxed warning for serious hepatic flares and low platelet counts, which can cause life-threatening thrombocytopenia. Other warnings include worsening kidney function, inflammatory reactions such as vasculitis and risks from improper injection. Regular blood tests are required.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
